Učitavanje...
Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study
BACKGROUND: Rivaroxaban could be an attractive alternative to low molecular weight heparin for the treatment of cancer‐associated venous thromboembolism (VTE) but the safety and effectiveness remain unclear. We examined risk of recurrent VTE and major bleeding associated with rivaroxaban treatment o...
Spremljeno u:
| Izdano u: | Cancer Med |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6434207/ https://ncbi.nlm.nih.gov/pubmed/30767432 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1997 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|